A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of ...

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.

Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising ...